Keyword: Darzalex

J&J's Darzalex made multiple myeloma history in May with an FDA nod in newly diagnosed patients. And now, it’s looking for a repeat.

Three years after its initial approval, Takeda’s Ninlaro may finally be ready to jump into a new indication.

Drugmakers have hoped that pairing their cancer drugs with I-O treatments would improve benefits. Not for Genmab and J&J.

Johnson & Johnson’s Darzalex just vaulted ahead of its myeloma competitors—and it has plenty of them.

While Johnson & Johnson’s multiple myeloma drug Darzalex has steadily won new approvals from the FDA, it continues to face obstacles in England.

J&J has succeeded in moving Darzalex earlier into multiple myeloma therapy, and it now has data that could help it win a first-line nod.

Johnson & Johnson may eventually tire of shelling out Darzalex payments to Genmab and take matters into its own hands, one analyst says.

Late last year, Johnson & Johnson widened Darzalex’s reach with some combo approvals. And now, it’s adding to that roster.